“For Cause” Inspections Find Galloping Clinical Trial Violation Rate
This article was originally published in The Pink Sheet Daily
Executive Summary
The violation rate for medical device clinical trial sponsors shot up in fiscal year 2007, hitting a 10-year high.
You may also be interested in...
Industry Involvement In Guidance Development Encouraged By FDA Working Group
In a report on best practices for guidance development, FDA encourages outside groups to submit their own draft guidance proposals to help make the overall process more efficient.
Industry Involvement In Guidance Development Encouraged By FDA Working Group
In a report on best practices for guidance development, FDA encourages outside groups to submit their own draft guidance proposals to help make the overall process more efficient.
FDA’s Office Of Regulatory Affairs Scrutinizes Recalls Process
ORA sets a 2012 priority of improving the efficiency of the recall process to help reach its overall enforcement and compliance goal of preventing public health emergencies.